Rosuvastatin is a potent statin used in the management of dyslipidemia and the prevention ofcardiovascular diseases. However, its low water solubility limits bioavailability and therapeuticoutcomes. This study outlines a nanotechnology-based method to enhance its solubility andabsorption of rosuvastatin. The process entails the formulation of rosuvastatin nanoparticlesthrough a combination of precipitation and ultrasonic techniques. Rosuvastatin is initially dissolvedin an organic solvent, such as acetone, and subsequently mixed with an aqueous phase containingstabilizers like Poloxamer 407 or PVP to induce precipitation. Ultrasound reduces particle sizeto 50-200 nm. Key parameters, including drug-to-stabilizer ratio, stirring speed, ultrasoundduration, and temperature, were systematically optimized to archive uniform, nanoscale particles.The resulting nanoparticles exhibit improved stability and solubility, achieving a 6.8-fold increasecompared to unmodified Rosuvastatin. Additionally, the application of nanotechnology safeguardsthe drug against gastric degradation, reduces the required dosage, and minimizes potential sideeffects. This approach offers promising applications for poorly soluble drugs and significantlyimproves therapeutic efficiency, marking a step forward in pharmaceutical development for betterpatient outcomes